UroGen Pharma Ltd. (URGN)

NASDAQ: URGN · Real-Time Price · USD
10.64
-0.07 (-0.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
-0.65%
Market Cap 449.00M
Revenue (ttm) 89.36M
Net Income (ttm) -115.38M
Shares Out 42.20M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,375,991
Open 10.65
Previous Close 10.71
Day's Range 10.51 - 11.08
52-Week Range 10.51 - 20.70
Beta 1.07
Analysts Strong Buy
Price Target 44.50 (+318.23%)
Earnings Date Nov 6, 2024

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2017
Employees 201
Stock Exchange NASDAQ
Ticker Symbol URGN
Full Company Profile

Financial Performance

In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $44.5, which is an increase of 318.23% from the latest price.

Price Target
$44.5
(318.23% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

15 days ago - Business Wire

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

16 days ago - Business Wire

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

16 days ago - Business Wire

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

19 days ago - Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today hi...

25 days ago - Business Wire

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks from the past week, aiming to spark ideas and discussions among retail investors. Veradigm Inc. is undervalued due to regulatory pre...

5 weeks ago - Seeking Alpha

UroGen Pharma: Choice Based On Near Term High Value PDUFA

Urogen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 pote...

5 weeks ago - Seeking Alpha

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO ...

6 weeks ago - Seeking Alpha

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

6 weeks ago - Business Wire

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda...

6 weeks ago - Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, toda...

7 weeks ago - Business Wire

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

PRINCETON, N.J,--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

7 weeks ago - Business Wire

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

2 months ago - Business Wire

UroGen Appoints Chris Degnan as Chief Financial Officer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

2 months ago - Business Wire

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

2 months ago - Business Wire

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Announces Patent Allowance.

3 months ago - Business Wire

UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector

UroGen Pharma stock is a strong buy due to its innovative RTGel technology and promising pipeline, including JELMYTO and UGN-102, targeting urological cancers. URGN's JELMYTO shows impressive clinical...

4 months ago - Seeking Alpha

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

4 months ago - Business Wire

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company specializing in novel therapies for urothelial and specialty cancers, today announced the successful comp...

4 months ago - Business Wire

UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer ...

4 months ago - Seeking Alpha

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

4 months ago - Business Wire

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

4 months ago - Business Wire

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod...

6 months ago - Business Wire

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...

6 months ago - GlobeNewsWire

UroGen: Q3 NDA Opens Hefty Revenue Opportunity

ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potenti...

6 months ago - Seeking Alpha